Abstract library

338 results for "serum samples".
#2783 Use of Plasma Proteins to Predict Progressive Disease in Patients with Small Intestinal Neuroendocrine Tumours
Introduction: Prediction of progression in small intestinal neuroendocrine tumors (SI-NET).
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Biomarkers
Presenting Author: MD PhD Roger Belusa
#16 Endoglin as indicator of metastatic neuroendocrine tumors of the pancreas
Introduction: Neuroendocrine tumors of the pancreas are rare, highly vascularized tumors. Endoglin, a Transforming Growth Factor-β co-receptor, is a marker for angiogenic endothelial cells. Angiogenesis is required for tumor progression and the development of metastases. Recently, endoglin expression was found to be a prognostic marker in pancreatic carcinomas. However, the role of endoglin in neuroendocrine pancreatic tumors has so far not been studied.
Conference: 7th Annual ENETS Conference (2010)
Category: Basic
Presenting Author: Patricia Kuiper
#20 Paraneoplastic antigen Ma2 (PNMA2) auto-antibodies as biomarkers for early small intestine neuroendocrine tumors detection
Introduction: Small intestine neuroendocrine tumors (NETs) comprise well-differentiated NET (benign carcinoid), well-differentiated neuroendocrine carcinoma (malignant carcinoid) and poorly differentiated neuroendocrine carcinoma (NEC). The majority of NET patients have developed liver metastases at the time of diagnosis and surgery is then seldom curative. Novel predictive, diagnostic and prognostic markers are thus needed to improve our capabilities to diagnose and cure these tumors. We have previously identified six novel marker genes for neuroendocrine tumor cells by using Affymetrix microarrays and advanced bioinformatics. One of this markers, the paraneoplastic antigen Ma2 (PNMA2), which is normally expressed only in nervous tissue, can in the process of carcinogenesis be detected in tumors located outside the nervous system. The finding that Ma2 is expressed in small intestine neuroendocrine primary tumors and their metastases made it interesting to screen whether antibodies against Ma2 are present in the serum of NET patients.
Conference: 7th Annual ENETS Conference (2010)
Category: Basic
Presenting Author: PhD Valeria Giandomenico
Authors: Cui T, Elgue G, Li S C, Hurtig M, ...
#68 Serum chromogranin A as tumor marker in neuroendocrine tumors
Introduction: Serum chromogranin A (CgA) is used as a tumor marker for neuroendocrine tumors (NETs).
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr. Svenja Nölting
#86 Structure of complications in acromegalic patients at a single institute
Introduction: Acromegaly leads to reduced life expectancy, with an increase in the mortality rate. From several retrospective cohort studies, the predominant outcome is serum growth hormone (GH) concentration. Other factors associated with increased mortality include duration of symptoms prior to diagnosis, duration of disease, older age at diagnosis and the presence of cardiovascular disease, diabetes mellitus (DM) and hypertension at diagnosis.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: OKH OKSANA OLEGOVNA KHYZHNYAK
#137 Extensive ""multitasking"" surgery for advanced neuroendocrine tumors is safe and effective
Introduction: Management of advanced NETs is controversial, related to degree of intervention; the pendulum is swinging towards a more aggressive interventional approach. Our Center's philosophy is to offer a systematic, planned multimodality treatment for patients with advanced NETs.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: MD MICHAIL K Shafir
#189 Matrix metalloproteinases (MMPs) and Tissue Inhibitors of Matrix Metalloproteinases (TMIPs) in GEP NET Patients – A Potential Prognostic Biomarkers for Metastases
Introduction: MMPs have the ability to degrade the extracellular matrix and are responsible for tumor invasion and metastases. Higher TIMP-1 levels are associated with low survival rate in some types of cancer.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Dr Jolanta Blicharz-Dorniak
#193 Paraneoplastic Antigen Ma2 Autoantibodies as Specific Blood Biomarkers for Detection of Early Recurrence of Small Intestine Neuroendocrine Tumors
Introduction: Small intestine neuroendocrine tumors (SI-NETs) are rare fatal cancers. Many patients develop metastatis before diagnosis. There is no available curative treatment for patients with metastasis.
Conference: 8th Annual ENETS Conference (2011)
Category: Basic
Presenting Author: Associate Profes Valeria Giandomenico
Authors: Cui T, Hurtig M, Li S C, Veronesi G, ...
#356 Activin A in Carcinoid Heart Disease: A Possible Role in Diagnosis and Pathogenesis
Introduction: Carcinoid heart disease (CHD), a complication of NETs, is characterized by right heart fibrotic lesions. In addition to serotonin, cytokines and growth factors with fibrogenic properties may play a role.
Conference:
Category: Basic
Presenting Author: MD, PhD Deidi S. Bergestuen
#498 Limitations of Chromogranin A in Clinical Practice
Introduction: Chromogranin-A (CgA) is the most accurate marker for the histological diagnosis of neuroendocrine tumors (NETs). However diagnostic usefulness of circulating CgA is controversial as several conditions, both neoplastic and non-neoplastic, may induce false positive increases of this marker.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Dr Vincenzo Marotta